<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 31 May 2021 07:39:36 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>张文宏领衔燃BiG，八位研发掌门人再决BB-King之巅｜年会盛况</title><link>https://mp.weixin.qq.com/s/Mmw3NhDGQg-bVJcKEo5J5w</link><description></description><content:encoded><![CDATA[张文宏领衔燃BiG，八位研发掌门人再决BB-King之巅｜年会盛况]]></content:encoded><pubDate>Mon, 31 May 2021 06:52:46 +0800</pubDate></item><item><title>IL7融合蛋白临床疗效初现</title><link>https://mp.weixin.qq.com/s/P8yNccGdy_SNNkKGVvDUGA</link><description></description><content:encoded><![CDATA[IL7融合蛋白临床疗效初现]]></content:encoded><pubDate>Sun, 30 May 2021 06:22:28 +0800</pubDate></item><item><title>盘点2021上市的抗体新药-（4）amivantamab-vmjw</title><link>https://mp.weixin.qq.com/s/nP8q8iWAJSXAC2L2SwxLmQ</link><description></description><content:encoded><![CDATA[盘点2021上市的抗体新药-（4）amivantamab-vmjw]]></content:encoded><pubDate>Sun, 30 May 2021 06:22:28 +0800</pubDate></item><item><title>重磅！FDA加速批准AMG510上市，KRAS-“不可成药”靶点的逆袭之路</title><link>https://mp.weixin.qq.com/s/4FAhtzkS_EFdIZVFmDpdLA</link><description></description><content:encoded><![CDATA[重磅！FDA加速批准AMG510上市，KRAS-“不可成药”靶点的逆袭之路]]></content:encoded><pubDate>Sat, 29 May 2021 07:20:49 +0800</pubDate></item><item><title>百亿补体抑制剂市场江湖风云再起</title><link>https://mp.weixin.qq.com/s/loZzObsbd4sr_STABD8K-w</link><description></description><content:encoded><![CDATA[百亿补体抑制剂市场江湖风云再起]]></content:encoded><pubDate>Fri, 28 May 2021 06:12:25 +0800</pubDate></item><item><title>FDA发布双特异性抗体研发指南</title><link>https://mp.weixin.qq.com/s/nJmbi1F12f7kpHGMq_t3HA</link><description></description><content:encoded><![CDATA[FDA发布双特异性抗体研发指南]]></content:encoded><pubDate>Thu, 27 May 2021 06:29:48 +0800</pubDate></item><item><title>中国生物药研发现状与未来</title><link>https://mp.weixin.qq.com/s/utqalrdRLVgYMDQpg2Tk-w</link><description></description><content:encoded><![CDATA[中国生物药研发现状与未来]]></content:encoded><pubDate>Wed, 26 May 2021 06:32:42 +0800</pubDate></item><item><title>2020细胞免疫疗法研究报告</title><link>https://mp.weixin.qq.com/s/UVPmOHnzOOuALdsCnfEw2A</link><description></description><content:encoded><![CDATA[2020细胞免疫疗法研究报告]]></content:encoded><pubDate>Tue, 25 May 2021 06:20:07 +0800</pubDate></item><item><title>Trastuzumab Deruxtecan: HER-2+实体瘤治疗的变革者</title><link>https://mp.weixin.qq.com/s/JJNDU0IeYg23HCXZeIeXzQ</link><description></description><content:encoded><![CDATA[Trastuzumab Deruxtecan: HER-2+实体瘤治疗的变革者]]></content:encoded><pubDate>Mon, 24 May 2021 06:45:49 +0800</pubDate></item><item><title>君实生物：一个被低估的企业</title><link>https://mp.weixin.qq.com/s/qaOXScltfCzvYw-km6hcCg</link><description></description><content:encoded><![CDATA[君实生物：一个被低估的企业]]></content:encoded><pubDate>Sun, 23 May 2021 06:31:02 +0800</pubDate></item><item><title>TACA靶向治疗进展：CAR-T和双抗</title><link>https://mp.weixin.qq.com/s/gzQK2DiQ_mpgNd8edBNHAw</link><description></description><content:encoded><![CDATA[TACA靶向治疗进展：CAR-T和双抗]]></content:encoded><pubDate>Sat, 22 May 2021 06:33:18 +0800</pubDate></item></channel></rss>